Santarus' budesonide MMX Phase III data in ulcerative colitis to be presented at DDW 2011

Santarus, Inc. (NASDAQ: SNTS) today announced that the budesonide MMX^® Phase III clinical program will be featured in two oral presentations at the Digestive Disease Week (DDW) Meeting being held at McCormick Place in Chicago on May 7-10, 2011.

The oral presentations are scheduled as follows:

Presenter: Simon Travis, DPhil, FRCP, Saturday, May 7, 2011 at 4:45 p.m. CT

• Oral presentation #S100AB in the Research Forum - Controlled Clinical Trials in Inflammatory Bowel Disease (IBD), Budesonide MMX^® 9 mg for induction of remission of mild-to-moderate ulcerative colitis: data from a multicenter, randomized, double-blind, placebo-controlled study in Europe, Russia, Israel and Australia

Presenter: William J. Sandborn, M.D., Monday, May 9, 2011 at 3:00 p.m. CT

• Oral presentation #S403 in the Topic Forum - What's New in IBD, Budesonide MMX^® 9 mg for the induction of remission of mild-to-moderate ulcerative colitis: data from a multicenter, randomized, double-blind, placebo-controlled study in North America and India

Santarus plans to file the presentation slides in a Form 8-K filing with the Securities and Exchange (SEC) on Monday, May 9, 2011.